ADC CXO服务
Search documents
药明合联(2268.HK):中期业绩增速可观 产能扩张中长期成长高度可期
Ge Long Hui· 2025-10-17 11:43
Core Viewpoint - The company has demonstrated robust growth in the first half of 2025, with significant increases in revenue, gross profit, and net profit, driven by a strong order backlog and competitive positioning in the ADC market [1][2]. Financial Performance - In H1 2025, the company achieved revenue of 2.7 billion yuan, a year-on-year increase of 62.2% - Gross profit reached 980 million yuan, up 82.2% year-on-year - Adjusted net profit (excluding interest and expenses) was 730 million yuan, reflecting a 69.6% increase year-on-year - Adjusted net profit (including interest income and expenses) stood at 800 million yuan, a 50.1% year-on-year growth - Reported net profit was 750 million yuan, marking a 52.7% increase year-on-year [1]. Order Backlog and Market Position - As of H1 2025, the company had an unfulfilled order total of 1.33 billion USD, a year-on-year increase of 57.9% - New contract amounts grew by 48.4% year-on-year, with North America showing the highest growth rate - The global ADC market is projected to reach 13.2 billion USD in 2024, with a compound annual growth rate (CAGR) of 34.0% from 2020 to 2024, and expected to grow to 66.2 billion USD by 2030, with an outsourcing rate of approximately 60% [1][2]. Market Share and Competitive Advantage - The company's market share in the ADC sector increased from 9.9% in 2022 to 22.2% in H1 2025 - The company collaborates with 13 out of the top 20 global pharmaceutical companies, reinforcing its leading position in the industry [1][2]. Strategic Expansion and Capital Expenditure - In H1 2025, the company signed 37 new iCMC projects, including 13 winning molecule projects, and added 3 new PPQ projects - The company plans to invest approximately 1.56 billion yuan in capital expenditures in 2025, with around 900 million yuan allocated to the Singapore base and about 450 million yuan to the Wuxi base - Total capital expenditures are expected to exceed 7 billion yuan by 2029, with new capacities including coupling raw liquids, coupling formulations, and payload linkers [2]. Investment Outlook - The company is positioned as a leader in the rapidly expanding ADC CXO industry, with strong technical capabilities and product delivery quality - Revenue forecasts for 2025-2027 are projected at 5.99 billion yuan, 8.24 billion yuan, and 10.51 billion yuan, representing year-on-year growth rates of 47.7%, 37.7%, and 27.5% respectively - Net profit forecasts for the same period are 1.51 billion yuan, 2.06 billion yuan, and 2.67 billion yuan, with growth rates of 41.5%, 36.2%, and 29.4% respectively [2].
药明合联(02268):中期业绩增速可观,产能扩张中长期成长高度可期
Guolian Minsheng Securities· 2025-10-16 08:50
Investment Rating - The investment rating for the company is "Buy" (maintained) [7] Core Insights - The company achieved a significant revenue growth of 62.2% year-on-year, reaching 2.7 billion yuan in the first half of 2025. The gross profit increased by 82.2% to 980 million yuan, and the adjusted net profit (excluding interest and expenses) rose by 69.6% to 730 million yuan [5][11] - The company has a robust order backlog of 1.33 billion USD, reflecting a year-on-year increase of 57.9%, with new contract signings growing by 48.4% [11] - The global ADC market is projected to reach 13.2 billion USD in 2024, with a compound annual growth rate (CAGR) of 34.0% from 2020 to 2024, and is expected to grow rapidly to 66.2 billion USD by 2030 [11] - The company’s market share in the ADC outsourcing service sector has increased from 9.9% in 2022 to 22.2% in the first half of 2025, solidifying its position as an industry leader [11] Financial Performance - For the first half of 2025, the company reported revenues of 2.7 billion yuan, with a gross profit of 980 million yuan and a net profit of 750 million yuan [5][11] - The company forecasts revenues of 5.99 billion yuan, 8.24 billion yuan, and 10.51 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 47.7%, 37.7%, and 27.5% [13][14] - The adjusted net profit is expected to be 1.51 billion yuan, 2.06 billion yuan, and 2.67 billion yuan for the same years, with growth rates of 41.5%, 36.2%, and 29.4% [13][14] Capital Expenditure and Expansion - The company plans to invest approximately 1.56 billion yuan in capital expenditures in 2025, with significant investments in its Singapore and Wuxi bases [12] - By 2029, total capital expenditures are expected to exceed 7 billion yuan, aimed at expanding production capacity for various ADC-related products [12]